Trends in Stimulant Prescription Fills and Dementia Care: Addressing the Gaps

Trends in Stimulant Prescription Fills and Dementia Care: Addressing the Gaps

Introduction:
Prescriptions for stimulants, primarily used to treat attention-deficit/hyperactivity disorder (ADHD), were increasing for adults even before the COVID-19 pandemic. The pandemic brought about policy changes that expanded access to prescription stimulants via telehealth. This article aims to explore the trends in stimulant prescription fills among commercially insured individuals and the need for clinical practice guidelines for adult ADHD care. Additionally, we will discuss the importance of dementia care and the management of sleep disturbances in patients with dementia.

ADHD Care and Stimulant Prescription Fills:
The percentage of enrollees with one or more prescription stimulant fills increased from 3.6% in 2016 to 4.1% in 2021. Notably, during 2020-2021, the percentage of females aged 15-44 years and males aged 25-44 years with prescription stimulant fills increased by more than 10%. The increase in stimulant prescriptions can be attributed to the growing recognition of ADHD in adults and the ease of access through telehealth. However, it is crucial to evaluate the benefits and potential harms of these policy changes.

The Need for Clinical Practice Guidelines for Adult ADHD Care:
While well-established guidelines exist for ADHD care in children and adolescents, there is a significant gap in guidance for adult ADHD care in the United States. This lack of guidelines poses a public health concern as it hinders accurate diagnoses and appropriate treatment for adults with ADHD. The increase in the percentage of adults receiving prescription stimulants during the COVID-19 pandemic emphasizes the need for comprehensive clinical recommendations to ensure safe and effective care for adult ADHD patients.

Challenges and Potential Harms of Stimulant Prescribing:
Stimulants offer substantial benefits for individuals with ADHD, but they also pose potential risks, including adverse effects, medication interactions, diversion, misuse, and overdoses. Clinicians from various specialties are approached for ADHD care, leading to differing levels of training and comfort with diagnosing and managing ADHD. Effective and judicious prescribing, along with patient monitoring, is essential to mitigate the potential harms associated with stimulant medications.

Dementia Care and Sleep Disturbances:
Dementia is characterized by a decline in memory and other cognitive skills, leading to a reduced ability to perform daily activities. Sleep disturbances are commonly observed in patients with dementia, along with symptoms like visual hallucinations, delusions, and trouble processing visual information. Treating sleep symptoms is crucial in dementia care, and medication options such as amitriptyline and lorazepam can be considered. Non-drug approaches, including exercise, light therapy, sleep routine, and pain control, also play a vital role.

Conclusion:
In conclusion, the increase in stimulant prescription fills among adults with ADHD highlights the need for clinical practice guidelines for adult ADHD care. The COVID-19 pandemic and policy changes have provided an opportunity to evaluate the benefits and potential harms of expanded access to prescription stimulants. Additionally, dementia care requires a comprehensive approach that addresses sleep disturbances and provides holistic management. Three actionable pieces of advice for clinicians are: 1) Develop and implement clinical practice guidelines for adult ADHD care; 2) Ensure judicious prescribing of stimulant medications, considering potential harms and monitoring patients closely; 3) Incorporate sleep management strategies into dementia care plans. By addressing these gaps and challenges, we can improve the quality of care for individuals with ADHD and dementia.